Can ivabradine be prescribed to a patient with a permanent pacemaker?

Can Ivabradine Be Used in Patients with Permanent Pacemakers?

Ivabradine is contraindicated in patients with pacemaker dependence (heart rate maintained exclusively by the pacemaker), but can be used in patients with demand pacemakers set to rates <60 bpm who maintain intrinsic sinus rhythm. 1

Key Distinction: Pacemaker Dependence vs. Demand Pacing

The critical factor is whether the patient has intrinsic sinus rhythm or is pacemaker-dependent:

Absolute Contraindication

• Pacemaker dependence (100% paced rhythm): Ivabradine is contraindicated because it works by inhibiting the If current in the sinoatrial node to slow heart rate 1. If there is no native sinus node activity, the drug cannot work and serves no purpose.

Relative Contraindication

• Demand pacemakers set ≥60 bpm: Ivabradine use is not recommended because dosing targets a heart rate of 50-60 bpm in adults 1. Patients with pacemakers programmed to maintain rates ≥60 bpm cannot achieve this target heart rate, making dose titration impossible. These patients were excluded from pivotal trials 1.

Acceptable Use

• Demand pacemakers set <60 bpm with preserved sinus rhythm: Ivabradine can be used if the patient maintains intrinsic sinus rhythm most of the time and the pacemaker only provides backup support. The 2021 ACC guidelines note that ivabradine is indicated for patients "mainly in sinus rhythm" and that "100% atrial pacing" is a contraindication 2.

Clinical Algorithm for Decision-Making

Step 1: Determine pacing dependency

• Review pacemaker interrogation: What percentage of time is the patient paced?
• If 100% paced → Do not use ivabradine 1

Step 2: If not pacemaker-dependent, check pacemaker settings

• Lower rate limit ≥60 bpm → Avoid ivabradine (cannot titrate to target) 1
• Lower rate limit <60 bpm → Proceed to Step 3

Step 3: Confirm underlying rhythm

• Must be in sinus rhythm ≥40% of the time (based on SHIFT trial criteria) 2
• Persistent/chronic atrial fibrillation → Contraindicated 3
• History of paroxysmal AF is acceptable if currently in sinus rhythm 2

Step 4: Assess for conduction disease

• If history of conduction defects (1st or 2nd degree AV block, bundle branch block), start at 2.5 mg twice daily rather than standard 5 mg dose 1

Important Caveats

Bradycardia Risk

Patients with pacemakers often have underlying conduction disease, increasing bradycardia risk with ivabradine 1. The pacemaker provides a safety net against severe bradycardia, but this doesn't eliminate the contraindication in pacemaker-dependent patients—it simply means the drug won't work.

Monitoring Requirements

• Regular cardiac rhythm monitoring is essential 1
• Adjust dose based on intrinsic heart rate when not paced 1
• If bradycardia develops (<50 bpm or symptomatic), decrease dose by 2.5 mg twice daily or discontinue if already on 2.5 mg 1

Real-World Evidence

A case report demonstrated successful ivabradine use in a patient with POTS and a dual-chamber pacemaker, showing it can be effective when intrinsic sinus rhythm is present 4. However, this remains off-label use requiring careful patient selection.

Atrial Fibrillation Considerations

Ivabradine increases AF risk (5.0% vs 3.9% per patient-year) 1. In patients with pacemakers who develop AF, ivabradine becomes both ineffective and contraindicated 3. Recent data suggests even higher AF risk than previously recognized 5, making vigilant rhythm monitoring essential.

The bottom line: Ivabradine requires functioning sinus node activity to work. Pacemaker-dependent patients lack this prerequisite, making the drug both ineffective and contraindicated.